The Orphan Regulation (EC) No 141/2000 has been successful in stimulating R&D investment and new medicinal products tailored for rare diseases, offering several interesting incentives for companies. These incentives include free access to scientific advice during non clinical and clinical drug development programs ('protocol assistance'); reduction in fees payable to EMA for review of the marketing authorisation and subsequent license maintenance fees, market protection in terms of market exclusivity in addition to a range of European and national incentives. This has favoured an increase in the number of applications submitted and, subsequently, granted.
the exceptional or conditional approval marketing authorization mechanisms, i.e. the company is either able or unable (respectively) to eventually provide a complete evidence package.
During the Orphan Drug sessions all the relevant procedures have been examined: from the designation, through the "protocol assistance", the designing of clinical trials (innovative approaches) and evaluation process during the centralised procedure.
Valuable experience from both the Regulatory Agency (EMA) and pharmaceutical industry has been illustrated outlining the current regulatory and R&D framework in the orphan drug field.
The need of a full application of the Orphan Regulation has been highlighted, claiming for a close collaboration with all stakeholders. Pharmaceutical industries should continue to work with regulators to generate appropriate evidence to support the use of novel medicines to treat these rare conditions and regulatory assessors also have to accept different approaches to ensure the protection of the patients' interests.
